Table 2.
FluSure XP® vaccination and H1N1 challenge studies
| Heterologous challenge | Measurement of protectiona | HI GMT to challenge(vaccine)bvirus | Outcomec | Ref. | Total EpiCC score(×102) | ||
|---|---|---|---|---|---|---|---|
| H1N1 Virus | Percentage of macroscopic pneumonia | Virus titers in nasal swabs | Virus titers in lungs | ||||
| MN02 H1β | Reduced | Reduced | Not available | 80 (381) | Protection | 7 | 5.38 |
| IA92 H1α | Significantly reduced | Significantly reduced | Not available | ≤20 (320) | Protection | 9 | 1.61 |
| CA09 H1pdm | Significantly reduced | Significantly reduced | Significantly reduced | ≤10 (53d) | Protection | 6 | 0.63 |
| OH10 H1γ | Significantly reduced | Not available | Significantly reduced | ≤10 (109) | Protection | 10 | 1.64 |
| MN11 H1γ | Significantly reduced | Significantly reduced | Significantly reduced | ≤20 (117) | Protection | 11 | 2.10 |
| IL08 H1α | Not significantly different | Significantly reduced | Significantly reduced | ≤20 (240) | Partial protection | 12 | ‐1.34 |
a
Significance of outcomes was as measured and reported in the original references.
b
HI GMT to the challenge and homologous viruses are shown.
c
The vaccine was considered protective if it reduced macroscopic pneumonia and virus titers in nasal swabs and/or in lungs collected at necropsy. If the vaccine significantly reduced virus titers, but not lung lesions, it was considered partially protective.
d
HI GMT to a heterologous γ‐cluster virus (A/Swine/OH/51145/2007 H1N1).